View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

TotalEnergies SE : Déclaration des Transactions sur Actions Propres

PARIS--(BUSINESS WIRE)-- Regulatory News: Dans le cadre de l’autorisation consentie par l’Assemblée générale ordinaire du 26 mai 2023 pour opérer sur ses actions et conformément à la réglementation relative aux rachats d'actions, TotalEnergies SE (LEI : 529900S21EQ1BO4ESM68) (Paris:TTE) (LSE:TTE) (NYSE:TTE) déclare ci-après les achats d’actions propres (FR0000120271) réalisés du 29 avril au 3 mai 2024 : Jour de la transaction Volume total journalier (en nombre de titres) Prix pondéré moyen journalier d'acquisition (en EUR/action) Montant des transactions (EUR) Cod...

 PRESS RELEASE

TotalEnergies : Assemblée générale ordinaire et extraordinaire du 24 m...

PARIS--(BUSINESS WIRE)-- Regulatory News: Les actionnaires de la Société sont invités à participer à l’Assemblée générale ordinaire et extraordinaire de TotalEnergies SE (Paris:TTE) (LSE:TTE) (NYSE:TTE) qui se tiendra vendredi 24 mai 2024, à 14 heures, à la Tour Coupole, 2 place Jean Millier, La Défense 6, 92 400 Courbevoie. L’Assemblée générale sera retransmise en direct en intégralité sur le site internet . Toutes les informations utiles relatives à cette Assemblée sont régulièrement mises à jour sur cette page du site. Les actionnaires peuvent exercer leur droit de vote préalablement ...

Stephane Foucaud
  • Stephane Foucaud

AUCTUS ON FRIDAY - 03/05/2024

AUCTUS PUBLICATIONS ________________________________________ ADX Energy (ADX AU)C; target price of A$0.75 per share: Raising new equity to fund a high impact activity programme – ADX has raised A$13.5 mm of new equity priced at A$0.105 per share. One free-attaching option will be issued for evert two placement shares with an exercise price of A$0.15 per share and an expiry date of 08/05/2026. The proceeds from the raise will fund (1) the production testing of the 450 m gas column encountered at ...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Aperam: In-line 1Q24 EBITDA, FCF marked by WC build, 2Q24 guidance below consensus. Ayvens: Taking the brakes off. BAM: Not the best start to the year. bpost: 1Q24 in line with consensus but beat vs INGF, no outlook yet. Brunel International: good set of 1Q24 results – 5% beat on EBIT, comforting trends. B&S Group: Preview - should be a non-event. DEME Group: Preview - should be a non-event. D'Ieteren: Febiac April registrations flat YoY, VW brands up 8.4%. GBL: NAV per share in ...

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

Sanofi - The Path to €120 (BUY, TP EUR120 [110], 7pgs)

This new analysis shows how Sanofi shares get to €120 (+c.30%) by end 2025. We have conducted a foundational analysis that investors can refer to over the next 18mths as Sanofi releases at least 15 P2 & P3 pipeline readouts. We show the upside potential from every single readout and show that just 4 drugs could add €18/share upon successful readouts. In addition to multiple readouts, the likely Consumer Health spin in Q4, the tolebrutinib overhang being resolved one way or another and a strong C...

Hermes International: 1 director

A director at Hermes International bought 1,220 shares at 2,298.000EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

Jean Danjou ... (+3)
  • Jean Danjou
  • Oliver Metzger
  • Thomas Zlowodzki

ODDO BHF Small & MIDCAP MORNING NEWS - 02/05/2024

Nous sortons GALP de notre liste ODDO BHF European Large Caps. La valeur a réalisé une performance de +31,3% depuis son entrée le 20 mars dernier. Notre analyste adopte ce jour une opinion Neutre (vs Surperformance) sur la valeur qui a atteint notre objectif de cours. - ...

Ahmed Ben Salem
  • Ahmed Ben Salem

GALP : Q1 2024 results beat expectations, reassuring outlook – recomme...

>Upstream: solid growth profile underpinned by discoveries in Namibia - Adjusted EBITDA for upstream activities totalled € 591m in Q1, 9% above expectations. The group is guiding for divisional EBITDA of € 2.1bn for 2024, which seems fairly conservative, in our view, and output >115 kboe/d, in line with our expectations. This output should increase by over 30% (+40 kboe/d) with the start-up of Bacalhau in Brazil at end-2025 and which should reach its plateau in 202...

Ahmed Ben Salem
  • Ahmed Ben Salem

GALP : Résultats T1 supérieurs aux attentes, outlook rassurant. Recomm...

>Upstream : un profil de croissance solide renforcé par les découvertes en Namibie - L’EBITDA T1 2024 ajusté de l’Upstream est ressorti à 591 M€ et 9% au-dessus des attentes. Le groupe guide sur un EBITDA 2024 de la division à 2.1 Md€ qui nous parait assez conservateur et une production >115 kbep/j en ligne avec nos attentes. Cette production devrait croitre de de plus de 30% (+40 kbep/j) avec le démarrage de Bacalhau au Brésil fin 2025 qui devrait atteindre son pl...

Jerôme Bodin
  • Jerôme Bodin

TF1 : Q1 in line - Outlook for the full year still solid

>Solid Q1 advertising trend driven by the success of TF1+ - On Tuesday, TF1 published its Q1 2024 results, which were followed by a conference call. They were in line with our forecasts for EBITA at € 37.3m (our forecast was € 37.5m). The Q1 advertising trend was solid, notably with a very good performance delivered by TF1+. This was an atypical quarter and marked by an increase in costs. The comparison base was notably relatively unfavourable for programming costs an...

Ahmed Ben Salem
  • Ahmed Ben Salem

GALP : Q1 2024 results: strong beat to consensus with robust cashflow

>Q1 2024: 12% beat on EBITDA, 23% for EBIT and 28% for NI - GALP has just released its Q1 2024 results with EBITDA of € 974m, 12% above the consensus and 14% above our estimates. EBIT came in at € 776m (up 88.8% q-o-q), 23.4% above the consensus. Adjusted net income was € 337m (+18.7% q-o-q) and 28.6% above the consensus. Robust results supported by refining - Upstream: adjusted EBITDA was € 591m (vs € 599m in Q4), 9% above the consensus with lower ...

Jerôme Bodin
  • Jerôme Bodin

TF1 : T1 conforme – Perspectives toujours solides sur l’ensemble de l’...

>Tendance publicitaire T1 solide tirée par le succès de TF1+ - TF1 a publié mardi ses résultats du T1 2024 et a tenu sa conférence téléphonique dans la foulée. Ils sont ressortis en ligne avec nos attentes avec un EBITA de 37,3 M€ alors que nous tablions sur 37,5 M€. La tendance publicitaire a été solide au T1 avec, notamment, une très bonne performance de TF1+. Ce trimestre est atypique et marqué par une hausse des coûts. L’effet de base était notamment peu favorable...

 PRESS RELEASE

Press Release: Beyfortus real-world evidence published in The Lancet s...

Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus no intervention1-6Results add to the consistent high efficacy of Beyfortus against medically attended RSV lower respiratory tract disease, shown in the pivotal clinical studies and the o...

 PRESS RELEASE

Communiqué de presse : Des données de vie réelle concernant Beyfortus ...

Communiqué de presse : Des données de vie réelle concernant Beyfortus publiées dans The Lancet montrent une réduction de 82 % des hospitalisations de nourrissons dues au VRS Des données de vie réelle concernant Beyfortus publiées dans The Lancet montrent une réduction de 82 % des hospitalisations de nourrissons dues au VRS De nouvelles données de vie réelle montrent que Beyfortus (nirsevimab) a permis de réduire sensiblement les infections des voies respiratoires inférieures dues au VRS chez les nourrissons, de même que les hospitalisations, au cours de la saison virale 2023-2024, compa...

Kering Sa: 2 directors

Two Directors at Kering Sa bought 135,294 shares at between 327.936EUR and 337.639EUR. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the l...

 PRESS RELEASE

City of Oceanside and ENGIE Announce a 30-year Comprehensive Energy P...

City of Oceanside and ENGIE Announce a 30-year Comprehensive Energy Project Oceanside, California and Houston, May 01, 2024 (GLOBE NEWSWIRE) -- The City of Oceanside, in collaboration with ENGIE North America (ENGIE), announced plans for a transformative energy initiative aimed at enhancing sustainability, reducing costs and fostering community engagement. This comprehensive 30-year initiative is projected to generate more than $26,000,000 in net savings for the City. It includes significant energy efficiency gains through a series of strategic measures, including: integrating 1.6 mega...

 PRESS RELEASE

Danone acquires Functional Formularies

Danone acquires Functional Formularies Press release – Paris, May 01, 2024 Danone acquires Functional Formularies Danone announces today it has successfully completed the acquisition of Functional Formularies, a leading whole foods tube feeding business in the US, from Swander Pace Capital. As part of the Renew Danone strategy, this acquisition strengthens Danone’s Medical Nutrition portfolio in the US by further expanding its enteral tube feeding ranges. Juergen Esser, Deputy CEO and CFO, said: “As a global leader in Medical Nutrition, we are delighted to welcome Functional Formularie...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch